# Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

> **NCT03960580** · PHASE3 · COMPLETED · sponsor: **Optinose US Inc.** · enrollment: 223 (actual)

## Conditions studied

- Chronic Rhinosinusitis

## Interventions

- **DRUG:** OPN-375

## Key facts

- **NCT ID:** NCT03960580
- **Lead sponsor:** Optinose US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960580, "Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03960580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*